These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. Valor LM; Viosca J; Lopez-Atalaya JP; Barco A Curr Pharm Des; 2013; 19(28):5051-64. PubMed ID: 23448461 [TBL] [Abstract][Full Text] [Related]
4. Histone post-translational modifications in Huntington's and Parkinson's diseases. Peña-Altamira LE; Polazzi E; Monti B Curr Pharm Des; 2013; 19(28):5085-92. PubMed ID: 23448464 [TBL] [Abstract][Full Text] [Related]
5. What's wrong with epigenetics in Huntington's disease? Valor LM; Guiretti D Neuropharmacology; 2014 May; 80():103-14. PubMed ID: 24184315 [TBL] [Abstract][Full Text] [Related]
6. Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue? Fischer A Neuropharmacology; 2014 May; 80():95-102. PubMed ID: 24486385 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic modifications in the nervous system and their impact upon cognitive impairments. Rudenko A; Tsai LH Neuropharmacology; 2014 May; 80():70-82. PubMed ID: 24495398 [TBL] [Abstract][Full Text] [Related]
10. Role of ERK signaling in activity-dependent modifications of histone proteins. Ciccarelli A; Giustetto M Neuropharmacology; 2014 May; 80():34-44. PubMed ID: 24486378 [TBL] [Abstract][Full Text] [Related]
11. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools. Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132 [TBL] [Abstract][Full Text] [Related]
12. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Stone TW; Darlington LG Br J Pharmacol; 2013 Jul; 169(6):1211-27. PubMed ID: 23647169 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. Konsoula Z; Barile FA J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970 [TBL] [Abstract][Full Text] [Related]
14. Dual influences of early-life maternal deprivation on histone deacetylase activity and recognition memory in rats. Albuquerque Filho MO; de Freitas BS; Garcia RC; Crivelaro PC; Schröder N; de Lima MN Neuroscience; 2017 Mar; 344():360-370. PubMed ID: 28089578 [TBL] [Abstract][Full Text] [Related]
15. Histone acetylation as a potential therapeutic target in motor neuron degenerative diseases. Garbes L; Riessland M; Wirth B Curr Pharm Des; 2013; 19(28):5093-104. PubMed ID: 23448465 [TBL] [Abstract][Full Text] [Related]
16. Small molecule modulators of histone acetylation and methylation: a disease perspective. Selvi BR; Mohankrishna DV; Ostwal YB; Kundu TK Biochim Biophys Acta; 2010; 1799(10-12):810-28. PubMed ID: 20888936 [TBL] [Abstract][Full Text] [Related]
17. Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins. Buuh ZY; Lyu Z; Wang RE J Med Chem; 2018 Apr; 61(8):3239-3252. PubMed ID: 28505447 [TBL] [Abstract][Full Text] [Related]
18. Targeting post-translational modifications of histones for cancer therapy. Hsu YC; Hsieh YH; Liao CC; Chong LW; Lee CY; Yu YL; Chou RH Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):69-84. PubMed ID: 26518898 [TBL] [Abstract][Full Text] [Related]
19. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Miller CA; Campbell SL; Sweatt JD Neurobiol Learn Mem; 2008 May; 89(4):599-603. PubMed ID: 17881251 [TBL] [Abstract][Full Text] [Related]
20. Targeting Histone Methylation in Cancer. McCabe MT; Mohammad HP; Barbash O; Kruger RG Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]